All News
Filter News
Found 2,924 articles
-
EMBR LABS ANNOUNCES PUBLICATION OF GROUNDBREAKING STUDY ON HOT FLASHES IN PROSTATE CANCER PATIENTS IN PRESTIGIOUS NATURE JOURNAL
12/21/2023
Embr Labs, Inc, makers of Embr Wave®, the leading temperature wearable, today announced the publication of "Feasibility of a Novel Wearable Thermal Device for Management of Bothersome Hot Flashes in Patients with Prostate Cancer" in Nature Journal's Prostate Cancer and Prostatic Diseases.
-
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
12/21/2023
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the signing of a binding Head of Terms (HoT) agreement for the commercialization of DONESTA® in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company.
-
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
12/20/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced positive topline results from the Phase 1 study evaluating the pharmacokinetics, safety, and exploratory efficacy of DARE-PDM1.
-
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
12/20/2023
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of a pediatric study of its marketed contraceptive ESTELLE® in adolescent women.
-
ShiraTronics Announces Landmark Achievement: World's First Implant of its Innovative Chronic Migraine System
12/19/2023
ShiraTronics, Inc., a trailblazing clinical-stage medical device company, today announced a landmark achievement with the successful implantation of its Chronic Migraine System in the world's first six patients.
-
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
12/13/2023
Daré Bioscience, Inc. today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH).
-
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
12/12/2023
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the results of its third ESR1 and Quality of Life Survey (EQUALS 3).
-
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
12/10/2023
Astellas Pharma Inc. announced the European Commission on December 7 approved VEOZATM 45 mg once daily for the treatment of moderate to severe vasomotor symptoms associated with menopause.
-
City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research
12/8/2023
City of Hope, one of the largest cancer research and treatment organizations in the United States, will present innovative research at this year’s San Antonio Breast Cancer Symposium, taking place Dec. 5 to 9 in San Antonio, Texas.
-
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
12/8/2023
Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.
-
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - December 8, 2023
12/8/2023
Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.
-
Digital Therapeutics Market - The Health Benefits and Business Potential
12/7/2023
Digital-native start-ups and healthcare incumbents can both play important roles in building and scaling digital therapeutics to improve the management of chronic health conditions.
-
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1
12/7/2023
Daré Bioscience, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed as a non-hormonal treatment option for moderate to severe dyspareunia, a symptom of VVA associated with menopause.
-
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium
12/5/2023
Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS).
-
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
12/4/2023
Daré Bioscience, Inc. today announced commencement of the Company’s pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive.
-
The company is hoping the topline results for Veozah, which won FDA approval in May, will support health technology assessments for reimbursement negotiations in Europe.
-
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
11/30/2023
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen.
-
Bayer and CrossBay Medical to develop novel Intrauterine System Inserter
11/30/2023
Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.
-
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
11/30/2023
Mithra announces that the US Food and Drug Administration has provided feedback regarding its new drug application marketing authorization filing in the United States.
-
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
11/29/2023
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) reported today interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic (PK) and early pharmacodynamic (PD) profile of current and several next generation compositions of its oral peptide platform (NCT05965167).